← SynDRA
ETOPOSIDE
SynDRA canonical compound SYN0002320 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | TOP2B |
|---|
| Mechanism of action | Topoisomerase inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- TOP2A
- TOP2B
- ABCB1
- ABCC1
- ABCC2
- ABCC3
- ABCC6
- ABCG2
- ALOX15
- CYP2E1
- CYP3A5
- NR1I2
Mechanisms of action (all sources)
- topoisomerase inhibitor
- TOP2A INHIBITOR
- DNA topoisomerase II inhibitor
- TOP2B INHIBITOR
- DNA topoisomerase II alpha inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ESR1
- CASP3
- SLCO1B3
- MTOR
- MC5R
- MLNR
- MMP1
- MMP9
- ABCC10
- MC3R
- NCOA1
- NCOA3
- NFE2L2
- NPY1R
- NPY2R
- NR3C1
- MC4R
- MAPK14
- MAPK3
- OPRK1
- MAPK1
- MAOA
- LCK
- KCNH2
- HTR6
- HTR3A
- HTR2C
- HTR2B
- HTR2A
- HTR1A
- HRH3
- HRH2
- OPRD1
- OPRM1
- HMGCR
- PDE3A
- UGT1A1
- TOP1
- TDP1
- TBXAS1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ANDR
- HSPB1
- STK33
- RARA
- PRGR
- NR5A2
- NF2L2
- MDR1
- MDM4
- MDM2
- IFNG
- GLI3
- ATF6
- GEMI
- GCR
- ESRRA
- CSTA
- CP3A4
- CASP7
- BRCA1
- BARD1
- ATXN2
- TP53
Drug classes
- Topoisomerase Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Enzyme Inhibitors
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitor
ATC classes
- L01C · PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
Cross-references
Synonyms
- AVOPEF
- Avopef
- Etopophos
- TOPOSAR
- Toposar
- VEPESID
- Vepesid
- etosid
- fytosid
- toposar
- zuyeyidal
- VP-16
- Etoposido
- Etoposidum
- Sintopozid
- NSC-141540
- VP-16-213
- Etoposide resolution mixture
- VePesid
- trans-Etoposide
- Lastet
- (-)-Etoposide
- Zuyeyidal
- Vepesid J
- Eposin
- Etoposidum [INN-Latin]
- Etoposide (VP16)
- VP 16 (pharmaceutical)
- Etoposido [INN-Spanish]
- Etopophos (phosphate salt)
- 4-Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
- VP 16213
- UNII-6PLQ3CP4P3
- NK 171
- CCRIS 2392
- HSDB 6517
- EINECS 251-509-1
Reported adverse events
- Nausea
- Myelosuppression
- Abdominal pain
- Rash
- Stomatitis
- Hypersensitivity
- Alopecia
- Hypertension
- Leukopenia
- Thrombocytopenia
- Death
- Hypotension
Look up ETOPOSIDE in the interactive SynDRA portal →